The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.
LJP 394 (abetimus sodium) is a unique drug that is specifically designed to lower production of antibodies to double-stranded DNA. These antibodies are believed to contribute to kidney damage in patients with Systemic Lupus Erythematosus (SLE). Rising levels of these antibodies seem to be associated with exacerbations of kidney disease that are known as "renal flares." Currently, anti-inflammatory and cytotoxic drugs are used to treat renal flares. Unfortunately, these drugs are often associated with certain unpleasant side effects. The purpose of this trial is to determine whether LJP 394 can delay or reduce the number of renal flares. It is possible that if renal flares can be delayed or reduced, patients may be able to take smaller amounts of anti-inflammatory or cytotoxic drugs and therefore suffer fewer of the side effects associated with these treatments.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
330
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Rheumatology Associates of North Alabama
Huntsville, Alabama, United States
Montgomery Rheumatology Associates
Montgomery, Alabama, United States
Arizona Arthritis & Rheumatology
Paradise Valley, Arizona, United States
Allergy and Rheumatology Medical Clinic
La Jolla, California, United States
Davida-USC Dialysis Center
Los Angeles, California, United States
Wallace Rheumatic Study Center
Los Angeles, California, United States
Private Practice
Los Angeles, California, United States
UCLA School of Medicine
Los Angeles, California, United States
Boling Clinical Trials
Rancho Cucamonga, California, United States
...and 72 more locations